Articles

31. A Focus On CNS (Central Nervous System) 5/11/2011
    Today, developing differentiated drugs that deliver demonstrable patient benefits and added value is more challenging than ever.
32. White Paper: The Art Of Compliance - Turning Compliance Into A Sustainable Business Advantage 5/11/2011
    The past few years have presented extraordinary regulatory and quality compliance challenges for pharmaceutical, biotechnology, and medical device companies. They are required to do more with less as a result of consolidation, restructuring, and economic uncertainty.
33. Late Phase Research 5/11/2011
    The post-marketing environment is evolving rapidly — and without the right strategy, new challenges can squeeze precious value out of your investment.
34. Early Clinical Development Solutions 5/11/2011
    In the New Health, where competition and technology are driving rapid change, dollars and potential delays matter more than ever. Making the right decisions in early development is critical to the success of your portfolio.
35. Data Driven Market Success 5/11/2011
    A Quintiles customer needed an experienced post-marketing ally who could plan for the unknown and design an observational study to eventually include several affiliates, thousands of sites, and more than 55,000 patients, with start-ups staggered over time.
36. Aptuit Blister Packaging Case Study 4/28/2011
    A client, in need of global blister packaging, had received an exorbitant estimate from a Clinical Packaging and Logistics provider other than Aptuit.
37. Mastering The Extended Clinical Supply Chain Whitepaper: Strategic Advantages For Clinical Trials 4/28/2011

    The core of any good clinical supply chain system is a supply management system that addresses all of the nuances of clinical supplies.

38. Maximizing The Success Of Your CRO Partnerships Whitepaper 4/28/2011

    It’s certainly true that pharmaceutical companies are under intense pressure to replenish pipelines and reverse a trend in which R&D returns are falling below the costs of capital.

39. Case Study: Product Development Of An Inhaled Protein 4/9/2010

    A small biotechnology company in the United States turned to Aptuit to support the development of their inhaled respiratory product. They had added confidence that their limited in-house capability would benefit from Aptuit’s substantial experience and capabilities in respiratory science projects, fulfilling their need for first-in-class capabilities in manufacturing, clinical packaging and logistics, bio-analytics and respiratory analytics. By Aptuit, Inc.

40. Product Development Of An Inhaled Protein 4/9/2010
    A small biotechnology company in the United States turned to Aptuit to support the development of their inhaled respiratory product. They had added confidence that their limited in-house capability would benefit from Aptuit’s substantial experience and capabilities in respiratory science projects, fulfilling their need for first-in-class capabilities in manufacturing, clinical packaging and logistics, bio-analytics and respiratory analytics. By Aptuit, Inc.